Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novan Inc (NOVN)

Novan Inc (NOVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,814
  • Shares Outstanding, K 141,514
  • Annual Sales, $ 4,900 K
  • Annual Income, $ -30,640 K
  • 60-Month Beta -0.25
  • Price/Sales 13.92
  • Price/Cash Flow N/A
  • Price/Book 9.26
Trade NOVN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/10/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year 0.11
  • Growth Rate Est. (year over year) -154.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4350 +10.16%
on 11/02/20
0.5795 -17.31%
on 11/03/20
-0.0308 (-6.04%)
since 10/23/20
3-Month
0.3000 +59.73%
on 09/04/20
0.7500 -36.11%
on 10/14/20
-0.0097 (-1.98%)
since 08/21/20
52-Week
0.2150 +122.88%
on 02/28/20
3.7200 -87.12%
on 12/26/19
-1.5008 (-75.80%)
since 11/22/19

Most Recent Stories

More News
Novan: 3Q Earnings Snapshot

MORRISVILLE, N.C. (AP) _ Novan Inc. (NOVN) on Friday reported a loss of $8.4 million in its third quarter.

NOVN : 0.4792 (-0.52%)
Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19MP0420...

NVS : 87.31 (-0.24%)
NOVN : 0.4792 (-0.52%)
Novan to Present at the Virtual Investor KOL Roundtable

Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that members of management will participate in the Virtual Investor KOL Roundtable on Tuesday, October 27, 2020 at 12:00 PM ET.

NOVN : 0.4792 (-0.52%)
Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors

- John M. Gay, Vice President, Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer

NOVN : 0.4792 (-0.52%)
OMI : 24.02 (+3.18%)
THC : 32.70 (+3.51%)
New Technologies Arise to Help Prevent the Spread of Diseases

, /PRNewswire/ -- Due to increasing awareness amongst consumers on hygiene and preventive healthcare, the global surface disinfectant market is anticipated to grow significantly in the coming years. The...

OPTI : 0.0456 (-9.52%)
RLFTF : 0.3915 (-13.29%)
TNXP : 0.5750 (-0.90%)
TTNP : 0.1840 (-10.02%)
NOVN : 0.4792 (-0.52%)
Novan Inc. and Verrica Pharmaceuticals Participate in Virtual Panel to Discuss Developing Treatments for Molluscum Contagiosum on SNN Network

LOS ANGELES, CA / ACCESSWIRE / September 22, 2020 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Virtual Panel, titled, "The Pursuit of Molluscum: Beetlejuice...

NOVN : 0.4792 (-0.52%)
VRCA : 9.63 (+1.80%)
Novan to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14 at 4:00 PM EDT -

NOVN : 0.4792 (-0.52%)
Lewy Body Dementia Treatment Market 2020 Swot Analysis, Top Key Players Forecast To 2025

The market study on the published by demonstrates the important aspects that are anticipated to shape the growth of the global Lewy Body Dementia Treatment market in the upcoming years. The market for...

AXON : 1.22 (-5.43%)
ESALF : 74.0500 (-2.57%)
LLY : 143.38 (-1.45%)
GSK : 36.74 (-0.78%)
JAZZ : 144.31 (+0.85%)
NVS : 87.31 (-0.24%)
NOVN : 0.4792 (-0.52%)
PFE : 36.52 (-0.49%)
DNPUF : 13.3000 (-2.21%)
TEVA : 9.61 (+1.37%)
Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial

Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be sufficient to fund costs associated with conducting an additional...

NOVN : 0.4792 (-0.52%)
Novan to Present at Virtual Life Sciences Investor Forum on June 25

Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company's President and Chief Executive Officer, will present a corporate overview at the Life Sciences...

NOVN : 0.4792 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company's product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through...

See More

Key Turning Points

2nd Resistance Point 0.4964
1st Resistance Point 0.4878
Last Price 0.4792
1st Support Level 0.4728
2nd Support Level 0.4664

See More

52-Week High 3.7200
Fibonacci 61.8% 2.3811
Fibonacci 50% 1.9675
Fibonacci 38.2% 1.5539
Last Price 0.4792
52-Week Low 0.2150

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar